



Technological Innovation Session I

Wednesday, April 13, 2022

09.00am – 10.30am

Central Time (Us and Canada)



INTUITIVE

DAY TIME

07.00 AM Los Angeles

09.00 AM Chicago

10.00 AM New York

11.00 PM Sao Paolo

03.00 PM London

04.00 PM Rome, Paris, Madrid

07.30 PM New Delhi

10.00 PM Hong Kong

11.00 PM Tokyo, Seoul

SCHEDULE

Chairs: Pier Cristoforo Giulianotti, Yuman Fong

- | | |
|-------------|--|
| 09.00 am | Welcome and opening by chairs |
| 09.05 am | Intuitive approach to healthcare and robotics
Gary Guthart |
| 09.15 am | Perspective on platforms
Bob Desantis |
| 09.25 am | The purpose and power of digital
Brian Miller |
| 09.35 am | Advancements in imaging
Sanjeev Dutta |
| 09.45 am | Q&A with
Gary Guthart, Bob Desantis, Brian Miller,
Sanjeev Dutta, Iman Jeddi, Julian Nikolchev |
| 10.30/45 am | End of work |

GENERAL INFORMATION

The event will be held on the Zoom Webinar platform

To participate it is necessary to register

[Click here to register](#)

At the end of the event, a certificate of attendance will be issued to the participants

If you have any questions, please do not hesitate to contact us: info@clinicalrobotics.com



Gary S. Guthart, Ph.D.

*Chief Executive Officer, Member of the Board
Intuitive*

Gary S. Guthart, Ph.D., is chief executive officer at Intuitive and a member of the board of directors, roles he has held since 2010. He draws from more than 25 years of medical, engineering, scientific, and management experience.

Dr. Guthart joined the company as part of the first engineering team in 1996 as a control systems analyst. He was promoted to vice president of engineering in 1999, senior vice president of product operations in 2002, and four years later, he was appointed president and chief operating officer.

Before joining Intuitive, Guthart was part of the core team developing foundational technology for computer-enhanced surgery at SRI International (formerly Stanford Research Institute), a renowned nonprofit scientific research organization. While at SRI, he also developed algorithms for vibration and acoustic control of large-scale systems. Guthart's first scientific experience came early in his career in a Human Factors Lab at NASA, supporting a team studying human performance assessment of pilots.

Guthart is on the board of directors for Illumina and is also a member of the board of directors for the Silicon Valley Leadership Group.

Guthart received a B.S. in engineering from the University of California, Berkeley. He earned an M.S. and a Ph.D. in engineering science from the California Institute of Technology.

INTUITIVE



Bob DeSantis

*Executive Vice President and Chief Product Officer
Intuitive*

Bob DeSantis is executive vice president and chief product officer at Intuitive. He leads the global teams that develop and manufacture the company's three robotic platforms—multiport, single port, and endoluminal—all novel platforms that are designed to help enable better outcomes for patient populations around the world. He is also responsible for global operations, program management, technical services, user experience, and product management.

Mr. DeSantis joined Intuitive in 2013 as vice president instruments & accessories new product introduction. His role was later expanded to include leading the product development, marketing, engineering, and operations teams for the instruments, accessories, and endoscope portfolios. DeSantis has also played a key role in the expansion and scaling of Intuitive's global manufacturing operations. Most recently, he was the executive vice president and general manager of instruments, accessories, and endoscopes, leading the global teams that design, manufacture, and market the company's robust portfolio of products.

DeSantis started his career at U.S. Surgical, where he was part of the research team that developed laparoscopic technologies that enabled the first wave of minimally invasive surgery. Later as part of Covidien, he served as vice president of R&D for Surgical Devices, leading the mechanical and energy devices organizations. He also led the group that developed the first commercialized single incision laparoscopic surgery.

DeSantis earned a B.S. and M.S. in mechanical engineering from the State University of New York, Buffalo. He also holds a certificate in innovation management from the Massachusetts Institute of Technology.

The Intuitive logo, featuring the word "INTUITIVE" in a blue, sans-serif font. The letter "I" is stylized with a small circle above it, resembling a drop or a surgical instrument component.



Sanjeev Dutta, M.D.

*Vice President and Business Leader, Fluorescence Imaging
Intuitive*

He also serves as a strategic advisor to Intuitive's digital, innovation, and investment efforts.

Prior to joining Intuitive, Dr. Dutta was a vice president at Johnson & Johnson, focusing on innovation, strategy, and M&A within their medical device companies. Before that, he was a professor in the Department of Surgery at Stanford University and a principal investigator of MISTRAL Lab, focusing on medical device development in collaboration with SRI International.

Dutta received his Doctor of Medicine degree from the University of Calgary and completed general surgery residency at Dalhousie University. He subsequently trained in Minimally Invasive Surgery at McMaster University and in Neonatal & Pediatric Surgery at the Hospital for Sick Children in Toronto. Dutta also holds a graduate degree in educational psychology from the University of Illinois and an MBA from the Stanford Graduate School of Business.

INTUITIVE



Iman Jeedi

*General Manager, Single Port Platform
Intuitive*

Iman Jeedi is the general manager of the Single Port Platform at Intuitive. Dr. Jeedi's team is responsible for design and development, product management, and manufacturing engineering of the Single Port System, Endoscopes, and Instruments & Accessories.

Since joining Intuitive in 2013, she has held multiple leadership roles in Engineering, Operations, and Quality.

Jeedi has more than 15 years of experience in the medical device industry, including five years at Abbott Laboratories, where she held multiple engineering and operations roles. Her work at Abbott contributed to the commercial release of the first FDA-approved implantable continuous glucose monitoring sensor.

Jeedi holds a B.A.Sc. in Mechanical Engineering from the University of British Columbia, an M.S. in Medical Engineering from the University of Washington, and a Ph.D. in Biomedical Engineering from the University of California Davis.

INTUITIVE



Brian Miller, Ph.D.

*Chief Digital Officer
Intuitive*

Brian Miller, Ph.D., is chief digital officer at Intuitive. Dr. Miller oversees all aspects of the company's digital business—strategy, solutions, operations, product management, infrastructure, privacy, security, and network operations. He brings more than 20 years of robotics and digital technology experience, with a clear focus on creating technical, clinical, and operational value for customers and new business value for the company.

Miller began his career in the field of robotic surgery at Computer Motion, where he developed software for two of the earliest robotic surgical systems—AESOP and ZEUS. Miller joined Intuitive when the two companies merged in 2003. Starting as a control systems analyst, he quickly rose through the ranks at Intuitive, earning key engineering roles with increasing responsibility: director of engineering, simulation & networking; director of advanced development—the group responsible for next-generation technology—and vice president, system engineering, a role he held until 2015. Most recently, Miller served as senior vice president and general manager of Systems, Imaging, and Digital, a role where he honed and expanded the company's digital strategy and offerings.

During his tenure at Intuitive, Miller has contributed to key innovations in robotic surgical systems and surgeon simulation capabilities, earning patents for 3-D telestration, adaptive video streaming, video content searching, and virtual reality simulation for surgeon training.

Miller earned a B.S. in electrical and computer engineering from Iowa State University. At Northwestern University, he earned an M.S. and Ph.D. in mechanical engineering with a focus on haptic interfaces and robotics. He also participated in the Advanced Management Program at Harvard Business School.



INTUITIVE



Julian Nikolchev

Senior Vice President, Corporate Development and Strategy

Intuitive

Julian Nikolchev is senior vice president, corporate development and strategy at Intuitive. He joined the company in 2019, bringing more than 25 years of experience in the development and commercialization of therapeutic medical devices, including start-up formation, fundraising, team building, R&D management, clinical and pre-clinical strategies, operations, and general management.

Nikolchev is the developer of several novel technologies and products in the field of arthroscopy, orthopedics, women's health, interventional cardiology, neuroradiology, and minimally invasive access and delivery of devices and drugs. He has been named inventor or co-inventor on more than 35 issued or pending patents. He founded and co-founded several medical device companies, including Pivot Medical, a hip arthroscopy and sports medicine company; CardioMind, an interventional cardiology and neuroradiology company; and ProDuct Health, a medical device company developing technology for the early detection and treatment of breast cancer. He also served on the board of directors for Neocis, Neptune Medical Devices, and Escala Medical.

Nikolchev received a B.S. and an M.S. in mechanical engineering from Stanford University and an M.S. in technology management from the Massachusetts Institute of Technology.

INTUITIVE



Pier Cristoforo Giulianotti, MD, FACS

*Professor and Chief, Division of General, Minimally Invasive and Robotic Surgery
University of Illinois at Chicago*

Prof. Giulianotti received his M.D. degree from La Scuola Normale of Pisa University, Italy. Beside a formal General Surgery Residency at University of Pisa, he has completed two additional Residencies in Digestive and Vascular Surgery. In 1998, he became Director of the General and Minimally Invasive Surgery Division at Misericordia Hospital in Grosseto, Tuscany (Italy) and, after 5 years, Head of the Department of General Surgery at the same Hospital. In 2000, he pioneered the new robotic technology, performing complex procedures such as formal hepatic resection, lung resection and pancreatoco-duodenectomy. He has developed one of the largest programs worldwide for Robotic Surgery: the Special School ACOI of Robotic Surgery now extending his expertise to one of the few training programs in the US for robotic surgery to target established surgeons as well as residents and fellows in training. Since 1979, he has published over 250 papers in scientific publications on several topics such as pancreatic, vascular, transplant, oncologic, digestive and robotic surgery. In early 2007, Prof. Giulianotti has been awarded with the prestigious Lloyd M. Nyhus Endowed Chair in Surgery at University of Illinois at Chicago and has been appointed Chief of the Division of General, Minimally Invasive and Robotic Surgery.

The exceptional innovations introduced to the field of surgery by Professor Giulianotti have been widely recognized by his peers. Hundreds of illustrious surgeons from all over the world have visited (and continue to do so) Professor Giulianotti to take advantage of his extraordinary knowledge and his outstanding ability to teach.





Yuman Fong, M.D., Sc.D. (Hon)

Dr. Yuman Fong is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center

Dr. Fong is best known for his extensive work in the field of liver and pancreatic surgery. He helped usher in robotic techniques for HPB surgery. He is editor of the SAGES Atlas of Robotic Surgery. For his clinical work, he was awarded the Layton F. Rikers Master Clinician Award from the SSAT. He has assisted in the design and deployment of many novel surgical tools. His work in medical engineering has led to his election to the American Institute of Medical and Biologic Engineering.

His laboratory focus is in design of gene and immune cell therapies for cancer. His leadership on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health. He is Founding Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press, official journal of the ASGCT). He has co-authored over 1000 papers and 22 textbooks. He has also been elected to the American Society of Clinical Investigation and to the National Academy of Medicine.



SUPPORTED BY

o
INTUITIVE